Evidence map›Paper›PMID 39991724›Full record

ArticleExperimental and therapeutic medicine2025

Effect of dasatinib on blood concentrations of sunitinib and adverse events in a patient with metastatic renal cell carcinoma treated with sunitinib: A case report.

Miki Takenaka Sato, Hideaki Yashima, Takuya Araki, Masashi Nomura, Kazuhiro Suzuki, Koujirou Yamamoto

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental and therapeutic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Miki Takenaka SatoDepartment of Pharmacy, Gunma University Hospital, Maebashi, Gunma 371-8511, Japan.
Hideaki YashimaDepartment of Clinical Pharmacology and Therapeutics, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan.
Takuya ArakiDepartment of Pharmacy, Gunma University Hospital, Maebashi, Gunma 371-8511, Japan.
Masashi NomuraDepartment of Urology, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan.
Kazuhiro SuzukiDepartment of Urology, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan.
Koujirou YamamotoDepartment of Pharmacy, Gunma University Hospital, Maebashi, Gunma 371-8511, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The combined use of sunitinib and other tyrosine kinase inhibitors (TKIs) is discouraged because of the increased risk of adverse events (AEs). Furthermore, plasma sunitinib levels are affected by drugs that affect CYP3A4 activity; therefore, caution should be exercised when using CYP3A4 inhibitors. In the present study, a 59-year-old Japanese man with metastatic renal cell carcinoma (RCC) was diagnosed with chronic myeloid leukemia (CML) while on sunitinib treatment and was simultaneously treated with sunitinib and dasatinib, a multi-TKI used for CML with moderate CYP3A4 inhibitory activity. The trough levels of sunitinib and

Indexed as

adverse eventschronic myeloid leukemiadasatinibmetastatic renal cell carcinomaN-desethyl sunitinibsunitinibtherapeutic drug monitoring

Identifiers

PMID39991724
PMCPMC11843194

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.